Physician

Mohsin T Alhaddad, MD

According to 2025 Medicare claims, Mohsin Alhaddad, MD (NPI: 1467624619) practices cardiology in the Jackson, TN market, with the plurality of this provider's patient population coming from Madison, TN. This provider's primary affiliated billing organization is APEX CARDIOLOGY PC (NPI: 1467494070; TIN: 481265159) and primary practice location at 38301-3930. Alhaddad is affiliated with the Aledade A2643 Primary Care MSSP Enhanced (ACO ID: A2643), participating under the MSSP model.

Alhaddad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,273 traditional Medicare patients, billed 7,933 HCPCS/CPT codes, and received $789,060 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 16,175 prescription claims across 1,575 beneficiaries totaling $2,557,696 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 24 claims. Open Payments data shows 105 records totaling $386,145. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $419,155 to $2,557,696. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $120,103 to $1,847.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,844	9,830	$757,979
2016	1,926	10,071	$774,238
2017	1,920	11,677	$1,346,831
2018	2,298	15,955	$1,267,428
2019	2,479	11,257	$1,065,448
2020	1,623	9,369	$1,232,594
2021	1,409	7,799	$1,013,115
2022	1,390	7,346	$832,220
2023	1,446	7,849	$724,477
2024	1,273	7,933	$789,060

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	891	8,099	$419,155
2016	1,272	13,831	$927,768
2017	1,392	19,491	$1,492,896
2018	1,504	19,465	$1,586,009
2019	1,645	17,777	$1,703,796
2020	1,619	16,734	$1,819,088
2021	1,549	16,699	$1,924,730
2022	1,640	15,641	$2,171,598
2023	1,588	15,467	$2,496,026
2024	1,575	16,175	$2,557,696

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	12	105	$114,894
2016	N/R	195	$63,046
2017	N/R	126	$3,140
2018	N/R	N/R	N/R
2019	N/R	11	$24,437
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	11	$576
2023	N/R	24	$3,095
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	677	691	$122
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	300	602	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	523	753	$80
93015	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician	305	306	$46
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	941	1,026	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	1,286	50,043	$965,107
Entresto	Sacubitril/Valsartan	454	18,680	$406,665
Farxiga	Dapagliflozin Propanediol	311	12,220	$223,493
Xarelto	Rivaroxaban	271	10,129	$183,281
Adempas	Riociguat	14	374	$164,808

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	75	$1,209	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	30	$384,936	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mohsin T. Alhaddad, MD?

Tedicare shows public-source Medicare data for Mohsin T. Alhaddad, MD (NPI 1467624619), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mohsin T. Alhaddad, MD have ACO affiliation data?

Mohsin T. Alhaddad, MD is shown with ACO affiliation data for Aledade A2643 Primary Care MSSP Enhanced (MSSP, ACO ID A2643).

What billing organization is linked to Mohsin T. Alhaddad, MD?

Mohsin T. Alhaddad, MD is linked to APEX CARDIOLOGY PC (billing NPI 1467494070) in the available physician profile data.

Does Mohsin T. Alhaddad, MD have Open Payments data?

Mohsin T. Alhaddad, MD has 105 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.